Clinical Significance of Major Angiogenesis-Related Effectors in Patients with Metastatic Breast Cancer Treated with Trastuzumab-Based Regimens

被引：3

作者：

Kourea, Helen P. ^{[1
]}

Dimitrakopoulos, Foteinos-Ioannis ^{[2
]}

Koliou, Georgia-Angeliki ^{[3
]}

Batistatou, Anna ^{[4
]}

Papadopoulou, Kyriaki ^{[5
]}

Bobos, Mattheos ^{[5
,6
]}

Asimaki-Vlachopoulou, Anthoula ^{[7
]}

Chrisafi, Sofia ^{[5
]}

Pavlakis, Kitty ^{[8
]}

Chatzopoulos, Kyriakos ^{[5
]}

Galani, Eleni ^{[9
]}

Pentheroudakis, George ^{[10
,11
]}

Pectasides, Dimitrios ^{[12
]}

Bafaloukos, Dimitrios ^{[13
]}

Res, Eleni ^{[14
]}

Papakostas, Pavlos ^{[15
]}

Koutras, Angelos ^{[2
]}

Kotoula, Vassiliki ^{[5
,16
]}

Fountzilas, George ^{[5
,17
,18
]}

机构：

[1] Univ Hosp Patras, Dept Pathol, Rion 26504, Greece

[2] Univ Patras, Univ Hosp, Med Sch, Div Oncol,Dept Med, Patras, Greece

[3] Hellen Cooperat Oncol Grp, Sect Biostat, Data Off, Athens, Greece

[4] Ioannina Univ Hosp, Dept Pathol, Ioannina, Greece

[5] Aristotle Univ Thessaloniki, Hellen Fdn Canc Res, Lab Mol Oncol, Thessaloniki, Greece

[6] Int Hellen Univ, Sch Hlth Sci, Dept Biomed Sci, Thessaloniki, Greece

[7] Histopathol & Cytol Lab, Thessaloniki, Greece

[8] Natl & Kapodistrian Univ Athens, Sch Med, Pathol Dept, Athens, Greece

[9] Metropolitan Hosp, Dept Med Oncol 2, Piraeus, Greece

[10] Univ Ioannina, Med Sch, Dept Med Oncol, Ioannina, Greece

[11] Soc Study Clonal Heterogene Neoplasia EMEKEN, Ioannina, Greece

[12] Hippokrateion Hosp, Dept Internal Med 2, Oncol Sect, Athens, Greece

[13] Metropolitan Hosp, Dept Med Oncol 1, Piraeus, Greece

[14] Agii Anargiri Canc Hosp, Dept Med Oncol 3, Athens, Greece

[15] Hippokrateion Hosp, Oncol Unit, Athens, Greece

[16] Aristotle Univ Thessaloniki, Fac Med, Sch Hlth Sci, Dept Pathol, Thessaloniki, Greece

[17] Aristotle Univ Thessaloniki, Thessaloniki, Greece

[18] German Oncol Ctr, Dept Med Oncol, Limassol, Cyprus

来源：

CANCER RESEARCH AND TREATMENT | 2022年 / 54卷 / 04期

关键词：

Breast neoplasms; HER2; Vascular endothelial growth factor A; VEGFR; Angiogenesis; Prognosis; ENDOTHELIAL GROWTH-FACTOR; PROGNOSTIC-SIGNIFICANCE; HER2; EXPRESSION; VEGFR1; DISCORDANCE; SURVIVAL; RNA;

D O I：

10.4143/crt.2021.748

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose Angiogenesis is a crucial phenomenon in the development and progression of breast cancer (BC), but the clinical significance of angiogenesis-related proteins in metastatic BC remains unknown. This study investigates the prognostic value of vascular endothelial growth factor receptors 1, 2, 3 (VEGFR1, VEGFR2, VEGFR3) as well as vascular endothelial growth factors A and C (VEGFA and VEGFC) in metastatic BC patients treated with trastuzumab-based regimens. Materials and Methods Two hundred female patients were included. Protein and mRNA expression of the studied angiogenesisrelated factors were evaluated by immunohistochemistry and quantitative polymerase chain reaction, respectively. Results High expression of VEGFA, VEGFC, VEGFR1, VEGFR2, and VEGFR3 in the tumor cells was observed in 43.5%, 24.2%, 36%, 29.5%, and 43%, respectively. Stromal elements expressed high levels of VEGFA, VEGFC, VEGFR1, VEGFR2, and VEGFR3 in 78.9%, 93.3%, 90.7%, 90.2%, and 74.8% of tumors with available data. High tumor cell expression of VEGFR1 was a favorable prognosticator for survival among patients with human epidermal growth factor receptor 2 (HER2)-positive tumors (hazard ratio [HR], 0.55; p=0.013). A trend towards longer progression-free survival was detected univariately for patients with HER2-negative tumors and high expression of VEGFR2 (HR, 0.60; p=0.059). Conclusion VEGFR1 and VEGFR2 seem to have significant prognostic value in BC patients with metastatic disease treated with trastuzumab-based regimens.

引用

页码：1053 / 1064

页数：12

共 27 条

[1] Crosstalk between HER2 signaling and angiogenesis in breast cancer: molecular basis, clinical applications and challenges [J].